Walking Provides Physical, Mental Benefits to Dialysis Patients

This article originally appeared here.
Share this content:
Walking Provides Physical, Mental Benefits to Dialysis Patients
Walking Provides Physical, Mental Benefits to Dialysis Patients

FRIDAY, Dec. 2, 2016 (HealthDay News) -- A simple program that includes a few minutes of walking a day appears to benefit patients on dialysis, according to research published online Dec. 1 in the Journal of the American Society of Nephrology.

Carmine Zoccali, M.D., from the Institute of Clinical Physiology, National Research Center in Reggio Calabria, Italy, and colleagues included 296 dialysis patients who were randomly assigned to either a low-intensity exercise program or a comparison group who underwent no formal exercise program. The low-intensity regimen included 20 minutes of walking at low-to-moderate speeds every second day, with the intensity gradually increasing over six months.

The average distance covered during a six-minute walking test in the exercise group gradually improved -- from about 1,100 feet at the start of the study to 1,200 feet six months later. In comparison, the group without the exercise program showed no increase in walking distance. Participants who did the walking program also improved in the sit-to-stand test. Mental function also improved significantly in the exercise group compared to the control group, the researchers reported.

"Poor physical functioning is perhaps the most pervasive and disabling disturbance in patients with advanced kidney disease who are on chronic dialysis," Zoccali said in a journal news release. "Our study shows that simple, home-based exercise programs hold potential for improving physical functioning in dialysis patients."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »